MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial
Links shared publicly online about this topic.
- 1,378total visits
MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial
MAP Pharmaceuticals, Inc. today announced that the Company initiated a trial to compare the pharmacokinetics (PK), safety and metabolic profiles of LEVADEX" orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
View full resource at news-medical.net
Tags: Migraine, Migraine Medication, Headache, Vascular Headache, Pharma, DHE 45, Migranal Nasal Spray, Pharmacokinetics
Most Recently Shared on February 16, 2010 at 1:02 pm By:
MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial: MAP Pharmaceuticals, Inc. today announced... http://bit.ly/cQAyXU
Advertisement
